姜黄水煎剂灌肠联合英夫利昔单抗治疗难治性溃疡性结肠炎疗效观察

王禾; 雷天能

doi:10.3969/j.issn.1671-038X.2019.03.13

姜黄水煎剂灌肠联合英夫利昔单抗治疗难治性溃疡性结肠炎疗效观察

王禾^,,
雷天能

- 宜宾市第一人民医院消化内科, 四川宜宾 644000

详细信息

作者简介:
王禾,男,本科,副主任医师,研究方向:炎症性肠病

通讯作者: 王禾,E-mail:zeyang200606@163.com

中图分类号: R574.62

收稿日期: 2018-10-22

Therapeutic effect of turmeric decoction enema combined with infliximab in the treatment of refractory ulcerative colitis

WANG He^,,
LEI Tian-neng

- Department of Gastroenterology, the First People's Hospital of Yibin, Sichuan, Yibin 644000, China

More Information

Corresponding author: WANG He, E-mail: zeyang200606@163.com

Received Date: 22 October 2018

摘要

摘要: [目的]观察姜黄水煎剂灌肠联合英夫利昔单抗（infliximab，IFX）治疗难治性溃疡性结肠炎（RUC）的临床疗效。[方法]将80例难治性溃疡性结肠炎患者按随机数字表法为观察组和对照组，各40例。对照组予以英夫利昔单抗治疗，观察组在对照组基础上联合姜黄水煎剂灌肠治疗，22周后观察2组临床症状、内镜发现、炎性指标及粪便钙卫蛋白。[结果]治疗1次后，2组无患者进入临床缓解，观察组治疗应答者多于对照组（P<0.05）；治疗3次后，观察组临床缓解及治疗应答者多于对照组（P<0.05）；治疗1次后，2组无患者黏膜愈合，观察组内镜应答者多于对照组（P<0.05）；治疗3次后及5次后，观察组内镜应答者均多于对照组（P<0.05）。治疗3次后及5次后，观察组CRP、IL-1、TNF-α、粪便钙卫蛋白低于对照组（P<0.05）。[结论]姜黄水煎剂灌肠联合IFX治疗RUC能加速患者临床症状缓解，促进患者肠黏膜恢复，使炎性指标降至更低水平。
- 难治性溃疡性结肠炎 /
- 姜黄素 /
- 灌肠
Abstract: [Objective] To observe the clinical efficacy of turmeric decoction enema combined with infliximab (IFX) in the treatment of refractory ulcerative colitis (RUC).[Methods] Eighty patients with refractory ulcerative colitis were randomly divided into observation group and control group, 40 patients in each group. The control group was treated with infliximab. The observation group was treated with turmeric decoction enema on the basis of the control group. After 22 weeks, the clinical symptoms, endoscopic findings, inflammatory markers and fecal calprotectin were observed. [Results] After treatment for 1 time, no patients in the two groups entered the clinical remission. The observation group responded more than the control group (P<0.05). After 3 treatments, the observation group had more clinical remission and treatment response than the control group (P<0.05). After treatment for 1 time, no mucosa healed in the two groups. The endoscopic responders in the observation group were more than the control group (P<0.05). After 3 treatments and 5 treatments, the endoscopy responders in the observation group were more than the control group(P<0.05). After treatment for 3 and 5 times, the CRP, IL-1, TNF-α and fecal calprotectin in the observation group were lower than those in the control group (P<0.05).[Conclusion] Treatment of RUC with turmeric decoction enema and IFX could accelerate the impreovement of clinical symptoms, promote the recovery of intestinal mucosa, and reduce the inflammatory index to a lower level.
- Refractory ulcerative colitis /
- curcumin /
- enema

HTML全文

参考文献(21)

[1]	中华医学会消化病学分会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见(2012年·广州)[J].胃肠病学, 2012, 17(12):763-781.
[2]	陈建林, 陈锦锋, 邓健敏, 等.硫唑嘌呤合加味愈疡汤对激素依赖型溃疡性结肠炎患者激素替代的临床研究[J].中国中西医结合消化杂志, 2016, 24(4):287-289.
[3]	Faubion WA, Loftus EV, Harmsen WS, et al.The natural history of corticosteroid therapy for inflammatory bowel disease:a population-based study[J].Gastroenterology, 2001, 121(2):255-260.
[4]	Ho GT, Chiam P, Drummond H, et al.The efficacy of corticosteroid therapy in inflammatory bowel disease:analysis of a 5-year UK inception cohort[J].Aliment Pharmacol Ther, 2006, 24(2):319-330.
[5]	刘秀艳, 高文艳.难治性溃疡性结肠炎研究进展[J].现代中西医结合杂志, 2017, 26(29):3302-3306.
[6]	中华医学会消化病学分会炎症性肠病学组.抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017)[J].协和医学杂志, 2017, 12(8):239-243.
[7]	Bernstein CN, Fried M, Krabshuis JH, et al.World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010[J].Inflamm Bowel Dis, 2010, 16(1):112-124.
[8]	Truelove SC, Witts LJ.Cortisone in ulcerative colitis:final report on a therapeutic trial[J].Br Med J, 1955, 2(4947):1041-1048.
[9]	中国中西医结合学会消化系统疾病专业委员会.溃疡性结肠炎中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志, 2017, 26(2):105-111, 120.
[10]	曹倩, 薛猛, 雷敏.234例难治性溃疡性结肠炎患者临床特征及治疗分析[J].中华消化杂志, 2011, 31(9):577-581.
[11]	Amin J, Huang B, Yoon J, et al.Update 2014:Advances to Optimize 6-Mercaptopurine and Azathioprine to Reduce Toxicity and Improve Efficacy in the Management of IBD[J].Inflammatory Bowel Diseases, 2015, 21(2):445-452.
[12]	杨俊, 金玉, 潘迪, 等.英夫利昔单抗治疗溃疡性结肠炎的效果及对炎症因子水平的影响[J].中国医药导报, 2017, 14(15):148-151.
[13]	贾燕, 潘元明, 陆晓娟, 等.英夫利昔在难治性及合并肠外表现的溃疡性结肠炎中的疗效及安全性分析[J].胃肠病学和肝病学杂志, 2018, 27(5):513-517.
[14]	Rutgeerts P, Sandborn WJ, Feaganb G, et al.Infliximab for induction and maintenance therapy for ulcerative colitis[J].N Engl J Med, 2005, 353(23):2462-2476.
[15]	Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology.Ulcerative colitis practice guidelines in adults:American College of Gastroenterology, Practice Parameters Committee[J].Am J Gastroenterol, 2010, 105(3):501-523.
[16]	郑静, 张铁, 韩呈武.粪便生物标志物在炎症性肠病诊疗中的应用进展[J].检验医学与临床, 2018, 15(15):2342-2346.
[17]	王彬辉, 章文红, 张晓芬, 等.姜黄素的药理及剂型研究进展[J].中华中医药学刊, 2013, 31(5):1102-1105.
[18]	Hanai H, Iida T, Takeuchi K, et al.Curcumin maintenance therapy for ulcerative colitis:randomized, multicenter, doubleblind, placebo-controlled trial[J].Clin Gastroenterol Hepatol, 2006, 4(12):1502-1506.
[19]	Lang A, Salomon N, Wu JC, et al.Curcumin in combination with mesalamine induces remission in patients with mild-tomoderate ulcerative colitis in a randomized controlled trial[J].Clin Gastroenterol Hepatol, 2015, 13(8):1444-1449.
[20]	胥媚, 刘榴, 甘华田.姜黄素治疗炎症性肠病的作用机制[J].成都医学院学报, 2015, 10(6):741-743.
[21]	张声生, 杨雪, 赵鲁卿, 等.清热除湿中药灌肠方治疗溃疡性结肠炎近期疗效的观察[J].中国中西医结合消化杂志, 2015, 25(6):401-405.